ATOPIC DERMATITIS (AD)

This study is testing whether a new oral medication called ENV-294 can safely reduce the severity and extent of moderate-to-severe eczema (atopic dermatitis) in adults. For 12 weeks, 64 participants will take either the drug or a placebo pill daily, with regular clinic checkups t…

This early-stage study aims to see if a new drug called GS101 works similarly to the existing treatment Dupixent for atopic dermatitis (eczema). Researchers will compare how the body processes both drugs, their safety, and immune responses in 294 healthy adult men in China. This …

This study follows patients with atopic dermatitis (eczema) who previously participated in CM512 trials to see how safe and effective the treatment remains over the long term. Researchers will track side effects and how well the treatment continues to control eczema symptoms. The…

This is the first study in humans to test the safety and how the body processes a new drug called ATTO-3712. It will involve healthy adults and people with moderate-to-severe atopic dermatitis (eczema). Researchers will give increasing doses to see how well it's tolerated and how…

This is the first study in humans testing a new drug called ARQ-234 for moderate to severe eczema (atopic dermatitis). Researchers will give single and multiple doses to healthy volunteers and people with eczema to check if it's safe, how the body processes it, and if it shows ea…

This study is testing whether CeraVe moisturizing cream can help maintain skin hydration and prevent flare-ups in adults with mild to moderate eczema. After participants get their eczema under control with a steroid cream, they'll use either CeraVe or a standard moisturizer for 6…

This early-stage study is testing a new drug called ZL-1503 for moderate-to-severe eczema (atopic dermatitis). Researchers will first give single doses to healthy volunteers to check safety, then give multiple doses to people with eczema to see how the body processes the drug and…

This early-stage study is testing a new gel called VC005 for teens with mild to moderate eczema (atopic dermatitis). The main goals are to check how safe it is and how the body processes it. The study will involve a small group of 10 participants aged 12 to 18.

This is an early-stage study to check the safety and how the body processes a new oral drug called LPX-TI641. It will involve about 48 adults with moderate-to-severe eczema (atopic dermatitis) or plaque psoriasis. Participants will take the drug or a placebo pill daily for 28 day…

This study is testing whether a special infant formula containing probiotics can help prevent eczema, a common first sign of allergies, in babies who have a family history of allergies. Researchers will enroll 400 healthy newborns and measure their skin health over time. The goal…

This small pilot study is testing whether a cream containing glycomacropeptide, a compound derived from milk, can help reduce the symptoms of eczema in children. Researchers will compare the special cream to a regular moisturizer in 20 children aged 2 to 12 with mild eczema. The …

This small, early-stage study aims to understand how nerves and immune cells interact in the skin of people with mild-to-moderate eczema (atopic dermatitis). Researchers will inject a small amount of Botox into eczema patches to see if blocking nerve signals reduces inflammation …

This study aims to understand if babies are born with 'self-attacking' antibodies that target their own skin cells, and if these antibodies are linked to developing eczema. Researchers will follow 500 newborns, some at high risk for eczema, for two years. They will check umbilica…